Defence Therapeutics Appoints Kwin Grauer to Its Board of Directors

December 09, 2022 3:30 PM EST | Source: Defence Therapeutics Inc.

Vancouver, British Columbia--(Newsfile Corp. - December 9, 2022) - Defence Therapeutics Inc. (CSE: DTC) (FSE: DTC) (OTC Pink: DTCFF) ("Defence" or the "Company"), a Canadian biopharmaceutical company specialized in the development of immune-oncology vaccines and drug delivery technologies, is pleased to announce the appointment of Mr. Kwin Grauer to its board of directors, effective immediately.

Mr. Kwin Grauer, CPA, CA, has more than 20 years' experience operating, buying and selling small and medium-size businesses. Kwin is a seasoned professional in financing, financial modeling and corporate restructuring. He has over 10 years of active board work to go along with his business experience and Chartered Professional Accountant Designation. He has served as a Board Member of Langara College, where he was Chair of the Finance and Audit Committee for 5 years and Board Chair for 2 years. Kwin currently serves as the Audit Committee Chair for Uniserve Communications Corp.

"We are pleased to welcome Kwin to our board of directors as a strong and proactive member. He will certainly be an excellent addition to our team as the Chair of the Audit Committee due to his extensive knowledge in the fields of accounting, business, and financing. Kwin also benefits from a large network in the US and has dealt with several venture capital entities, which should help elevate Defence's presence and development in the US, including potential business, partnerships and financing," mentioned Sebastien Plouffe, Chief Executive Officer of Defence Therapeutics.

In connection with Mr. Grauer's appointment to the board of directors, Defence has granted to him incentive stock options to purchase 100,000 common shares of Defence pursuant to and in accordance with the terms and conditions of Defence's stock option plan, subject to any regulatory approval. Each stock option vests immediately and is exercisable at a price of $2.03 per share for a period of three years from the granted date.

About Defence:
Defence Therapeutics is a publicly-traded biotechnology company working on engineering the next generation vaccines and ADC products using its proprietary platform. The core of Defence Therapeutics platform is the ACCUMTM technology, which enables precision delivery of vaccine antigens or ADCs in their intact form to target cells. As a result, increased efficacy and potency can be reached against catastrophic illness such as cancer and infectious diseases.

For further information:
Sebastien Plouffe, President, CEO and Director
P: (514) 947-2272

Cautionary Statement Regarding "Forward-Looking" Information

This release includes certain statements that may be deemed "forward-looking statements". All statements in this release, other than statements of historical facts, that address events or developments that the Company expects to occur, are forward-looking statements. Forward-looking statements are statements that are not historical facts and are generally, but not always, identified by the words "expects", "plans", "anticipates", "believes", "intends", "estimates", "projects", "potential" and similar expressions, or that events or conditions "will", "would", "may", "could" or "should" occur. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results may differ materially from those in the forward-looking statements. Factors that could cause the actual results to differ materially from those in forward-looking statements include regulatory actions, market prices, and continued availability of capital and financing, and general economic, market or business conditions. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Forward-looking statements are based on the beliefs, estimates and opinions of the Company's management on the date the statements are made. Except as required by applicable securities laws, the Company undertakes no obligation to update these forward-looking statements in the event that management's beliefs, estimates or opinions, or other factors, should change.

Neither the CSE nor its market regulator, as that term is defined in the policies of the CSE, accepts responsibility for the adequacy or accuracy of this release.

To view the source version of this press release, please visit